"Its great to see funders continue to pump BHRT with positive cash. It seems evident that they believe in this company's future and where the technology is heading. Their patents are worth more and more everyday in my opinion!"??
1) The type of "funders" being utilized, Asher, Magna, Fourth Man, Daniel James, etc are known commonly as "lenders or money sources of LAST RESORT" and for the most part only lend to cash desperate penny stock companies. They offer the worst financing terms a company can get, aka "convertible debt" and stiff interest rates, and dilution, dilution and more dilution. They, these "lenders", IMO could care less about the company and don't "believe in the company's future", they only believe in making piles of money FAST and QUICK and w/ built in guarantees that they win, almost always, no matter what- like the house in Vegas.
2) If one reads the 10-K filings, most of BHRT's key patents are already expired or are expiring soon (as in maybe a yr or 2 more at the most). Everything else they license (they really haven't invented much of anything on their own, or original, they just license it from others, for example Adipocell, which not that long ago was named Lipicell. BHRT didn't invent it, they just pay a license to use it, someone else's tech). The 10-K also says that many "key" licenses regarding key products have also "lapsed". See last 10-K filing, end of yr 2013.
10-K:
"We hold limited patent and other intellectual property rights, and our success will be dependent in large part on safeguarding our existing intellectual property rights and obtaining patent and other proprietary protection for our product candidates.
We hold limited patent rights in our product candidates. Our MyoCath product candidate is protected by a patent, expiring in September 2017, in which we have an irrevocable co-exclusive license. Our MyoCell product candidate is no longer protected by patents, which means that competitors will be free to sell products that incorporate the same or similar technologies that are used in MyoCell without infringing our patent rights. As a result, MyoCell, if approved for use, may be vulnerable to competition in the form of products that use the same or similar technologies. We have previously licensed certain patents and patent applications relating to our MyoCell product candidate. These licenses have all lapsed as of the date of this report,"
